Information Provided By: 
Fly News Breaks for December 6, 2016
TEVA
Dec 6, 2016 | 06:35 EDT
Citi analyst Liav Abraham says the departure of Teva Pharmaceutical's head of generics, Siggi Olafsson, was unexpected and likely to "further dampen" near-term sentiment. The news is likely to raise questions regarding the strategy and strength of the company's generics business, Abraham tells investors in a research note. The analyst has a Buy rating on Teva with a $75 price target.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
